Ablative Solutions Welcomes Hypertension Leader to its Scientific Advisory Board

KALAMAZOO, Mich., Feb. 10, 2015 /PRNewswire/ -- Ablative Solutions, Inc., a venture-backed, privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today the addition of Michael Weber, MD, FACP, FACC, FAHA, to its Scientific Advisory Board. Dr. Weber is a distinguished expert in the areas of hypertension and preventive cardiology.  He is currently Professor of Medicine at SUNY Downstate College of Medicine in Brooklyn, New York.  He is the Editor-in-Chief of The Journal of Clinical Hypertension.  Dr. Weber was one of the founders of The American Society of Hypertension and has served as its President. 

Ablative Solutions, Inc., has developed a patented device, the Peregrine System™, which is a percutaneous catheter designed to deliver diagnostic and therapeutic agents through vessel walls to the outer region of arteries.  The Peregrine System has been cleared by the U.S. Food and Drug Administration (FDA) for the infusion of diagnostic and therapeutic agents into the perivascular area. 

Ablative Solutions is currently investigating the use of the Peregrine System in a clinical study in Europe intended to secure a CE Mark. The System is being evaluated for renal denervation, providing a treatment that delivers therapy directly to the nerves that run along the perimeter of the renal artery. The interruption of these nerve pathways may have therapeutic implications for hypertension, metabolic syndrome, congestive heart failure and obesity.  The system is not currently cleared or approved in the U.S. for renal denervation, or for the treatment of hypertension, metabolic syndrome, congestive heart failure or obesity.

"I am pleased to be joining the advisors to Ablative Solutions, which has conducted in-depth research on chemical neurolysis.  Hypertension is a serious public health issue.  The approach being pursued by the company toward sympathetic nerve modulation may provide a valuable addition to therapies for this condition," observed Dr. Weber.

In welcoming Dr. Weber to ASI's Scientific Advisory Board, Ablative Solutions President Vartan Ghazarossian, PhD, recognized Dr. Weber's extensive experience in both the clinical and regulatory arenas related to hypertension therapies.  "We are honored to have the guidance of Dr. Weber as our company enters the clinical stage," Dr. Ghazarossian stated.

Ablative Solutions was founded by two proven medical device entrepreneurs, Tim Fischell, MD, and David Fischell, PhD.  Development efforts have been led by ASI President, Vartan Ghazarossian, PhD, and Tim Fischell, MD, CEO. The company has pioneered the development of novel device-chemistry combination therapy. The Peregrine System uses a unique, patented technology to deliver diagnostic and therapeutic agents directly to the perivascular region that surrounds blood vessels.

Forward-Looking Statements

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward-looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. ASI's actual results may differ materially from ASI's historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to ASI's ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, ability to hire required personnel, the risk of whether products result from development activities, protection of ASI's intellectual property portfolio, the risk associated with obtaining the necessary regulatory approvals, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other potential factors.

For more information:
Vartan Ghazarossian, PhD
President
(650) 321-6884
http://www.ablativesolutions.com 

SOURCE Ablative Solutions, Inc.

Related Links

http://www.ablativesolutions.com